Zepbound Can Prevent Diabetes; Menopause and Cognition; Tandem’s Insulin Pump Update

In a phase III study of adults with pre-diabetes and obesity or overweight, tirzepatide (Zepbound) reduced the risk of developing type 2 diabetes by 94% over a 3-year period, Eli Lilly announced.

In related news, real-world data on patients with obesity but without diabetes found lower incidence of type 2 diabetes in tirzepatide versus semaglutide (Wegovy) users. (eClinicalMedicine)

Researchers in Health Affairs estimated that Medicare coverage of anti-obesity medications would increase annual spending by $3 billion to $6 billion.

Severe menopausal symptoms were associated with a 74% higher odds of mild cognitive impairment in postmenopausal women. (Menopause)

A resilience-building program for adolescents with type 1 diabetes improved diabetes distress and self-management but had no impact on HbA1c levels. (JAMA Network Open)

Tandem Diabetes Care said an update is now available to its Apple iOS t:connect mobile app to address a problem with its t:slim X2 insulin pump where the battery rapidly drained.

Higher aldosterone and renin in males were tied to increased waist circumference, waist-to-hip ratio, fat mass, and decreased lean body and muscle mass. As for females, higher renin — but not aldosterone — was linked with increased waist circumference, waist-to-hip ratio, and cardiac adiposity. (Journal of Clinical Endocrinology & Metabolism)

Patients wondering whether their insurance covers GLP-1 drugs for weight loss can use a tool offered by healthcare start-up Ro to find out. (CNBC)

Capsules containing an investigational γ-aminobutyric acid (GABA) analogue significantly reduced average daily pain score in a phase III trial of Chinese patients with diabetic peripheral neuropathic pain. (JAMA Network Open)

High levels of the lipid metabolites HDL, 3-hydroxybutyrate, and sphingomyelins were linked with a decreased risk of incident osteoporotic fractures in females. (Scientific Reports)

U.S. healthcare providers are receiving cease-and-desist letters from Eli Lilly regarding their promotion of compounded versions of tirzepatide. (Reuters)

Real-world data added more evidence for the continued reliability of 1-year serum thyroglobulin levels in the follow-up of differentiated thyroid cancer patients. (Journal of Clinical Endocrinology & Metabolism)

Please enable JavaScript to view the

comments powered by Disqus.